KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to -$11.6 million.

  • Rigel Pharmaceuticals' Cash from Financing Activities rose 143.40% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 152.60%. This contributed to the annual value of -$11.6 million for FY2024, which is 163.38% down from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Cash from Financing Activities is -$11.6 million, which was down 163.38% from $18.4 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Cash from Financing Activities registered a high of $62.7 million during FY2021, and its lowest value of -$11.6 million during FY2024.
  • For the 3-year period, Rigel Pharmaceuticals' Cash from Financing Activities averaged around $4.4 million, with its median value being $6.5 million (2022).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 398.57% in 2021, then plummeted by 163.38% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Cash from Financing Activities stood at $12.6 million in 2020, then skyrocketed by 398.57% to $62.7 million in 2021, then tumbled by 89.55% to $6.5 million in 2022, then surged by 180.41% to $18.4 million in 2023, then plummeted by 163.38% to -$11.6 million in 2024.